Every biosimilar switch strategy that fails, fails at the same point: someone made a sourcing decision based on the manufacturer’s […]

How life sciences talent teams can map influence networks, identify hidden innovators, and outmaneuver competitors using publicly available IP data

Colchicine cost nine cents a pill for more than two centuries. Then, in 2009, a company ran a 185-patient trial

The conventional wisdom about Russia’s pharmaceutical market runs something like this: foreign companies localize drug packaging in Russia to comply

The pharmaceutical patent landscape in Europe has shifted in ways that most of the industry’s public commentary has missed. The

The 505(b)(2) pathway is the pharmaceutical industry’s most capital-efficient regulatory route, and it is widely misunderstood. Ask ten drug developers

The $50 Million Problem Nobody Wants to Talk About Most pharmaceutical executives treat patent litigation as a legal department problem.

The pharmaceutical industry’s patent defense system is a machine built on a single assumption: that the price of a drug

An investigative deep-dive for commercial leads, market access directors, and C-suite executives who negotiate with OptumRx, Express Scripts, and CVS